Gregory Richard Schwartz, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heptanoic Acids | 19 | 2012 | 344 | 2.240 |
Why?
|
Pyrroles | 19 | 2012 | 1125 | 1.650 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 19 | 2011 | 3245 | 1.010 |
Why?
|
Anticholesteremic Agents | 11 | 2009 | 967 | 0.850 |
Why?
|
Angina, Unstable | 11 | 2011 | 888 | 0.680 |
Why?
|
Acute Coronary Syndrome | 8 | 2012 | 2190 | 0.480 |
Why?
|
Myocardial Ischemia | 9 | 2012 | 2110 | 0.430 |
Why?
|
Coronary Disease | 4 | 2005 | 5911 | 0.320 |
Why?
|
Sulfhydryl Compounds | 1 | 2009 | 301 | 0.300 |
Why?
|
Myocardial Infarction | 14 | 2011 | 11458 | 0.300 |
Why?
|
Hypercholesterolemia | 3 | 2012 | 1141 | 0.280 |
Why?
|
Prescription Fees | 1 | 2007 | 153 | 0.260 |
Why?
|
Ischemic Attack, Transient | 1 | 2011 | 874 | 0.250 |
Why?
|
Cholesterol | 4 | 2011 | 2902 | 0.240 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2007 | 348 | 0.240 |
Why?
|
Cholesterol, LDL | 6 | 2009 | 2378 | 0.220 |
Why?
|
Cholesterol, HDL | 1 | 2009 | 1810 | 0.210 |
Why?
|
Fluorobenzenes | 1 | 2004 | 179 | 0.200 |
Why?
|
Stroke | 7 | 2011 | 9715 | 0.200 |
Why?
|
Atrial Fibrillation | 2 | 2011 | 5031 | 0.180 |
Why?
|
Thiazolidinediones | 1 | 2003 | 460 | 0.170 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2003 | 481 | 0.170 |
Why?
|
Secondary Prevention | 5 | 2009 | 1470 | 0.170 |
Why?
|
Drug Costs | 1 | 2007 | 1183 | 0.160 |
Why?
|
Research Design | 2 | 2009 | 6174 | 0.160 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 858 | 0.150 |
Why?
|
Drug Prescriptions | 1 | 2007 | 1669 | 0.150 |
Why?
|
Syndrome | 5 | 2007 | 3268 | 0.120 |
Why?
|
Acute Disease | 6 | 2005 | 7236 | 0.120 |
Why?
|
Sulfonamides | 1 | 2004 | 1977 | 0.120 |
Why?
|
Phospholipids | 2 | 2009 | 787 | 0.110 |
Why?
|
Phospholipases A2, Secretory | 1 | 2012 | 30 | 0.100 |
Why?
|
Pyrimidines | 1 | 2004 | 3027 | 0.100 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2012 | 127 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2012 | 10203 | 0.090 |
Why?
|
Serum Amyloid A Protein | 2 | 2007 | 126 | 0.090 |
Why?
|
Drug Administration Schedule | 4 | 2011 | 4845 | 0.090 |
Why?
|
Heart | 1 | 2003 | 4403 | 0.090 |
Why?
|
Recurrence | 6 | 2009 | 8426 | 0.080 |
Why?
|
Medicare | 1 | 2007 | 6774 | 0.080 |
Why?
|
Esters | 1 | 2009 | 211 | 0.080 |
Why?
|
Apolipoprotein A-I | 1 | 2009 | 299 | 0.080 |
Why?
|
C-Reactive Protein | 4 | 2012 | 3820 | 0.080 |
Why?
|
Double-Blind Method | 8 | 2012 | 12333 | 0.070 |
Why?
|
Reimbursement, Incentive | 1 | 2012 | 542 | 0.070 |
Why?
|
Apolipoproteins B | 2 | 2009 | 385 | 0.070 |
Why?
|
Amides | 1 | 2009 | 449 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2011 | 10754 | 0.070 |
Why?
|
Health Care Reform | 1 | 1995 | 1247 | 0.060 |
Why?
|
Apolipoproteins | 2 | 2004 | 326 | 0.060 |
Why?
|
Least-Squares Analysis | 1 | 2004 | 368 | 0.060 |
Why?
|
Treatment Outcome | 8 | 2011 | 64572 | 0.050 |
Why?
|
Transcription Factors | 1 | 2003 | 12116 | 0.050 |
Why?
|
Economics, Pharmaceutical | 1 | 2003 | 87 | 0.050 |
Why?
|
Tissue Plasminogen Activator | 1 | 2009 | 1163 | 0.050 |
Why?
|
Chromans | 1 | 2003 | 117 | 0.050 |
Why?
|
Humans | 30 | 2012 | 760740 | 0.050 |
Why?
|
Antigen-Antibody Complex | 1 | 2004 | 509 | 0.050 |
Why?
|
CD40 Ligand | 1 | 2004 | 521 | 0.050 |
Why?
|
Patient-Centered Care | 1 | 2012 | 1419 | 0.050 |
Why?
|
Angina Pectoris | 2 | 2004 | 959 | 0.050 |
Why?
|
Quality Assurance, Health Care | 1 | 2012 | 2164 | 0.050 |
Why?
|
Survival Analysis | 3 | 2012 | 10072 | 0.050 |
Why?
|
Students, Medical | 1 | 1995 | 1936 | 0.050 |
Why?
|
Incidence | 3 | 2011 | 21339 | 0.050 |
Why?
|
Lipoproteins, LDL | 1 | 2004 | 642 | 0.050 |
Why?
|
Reactive Oxygen Species | 1 | 2009 | 2137 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2012 | 39062 | 0.040 |
Why?
|
Lipoproteins, HDL | 1 | 2005 | 675 | 0.040 |
Why?
|
Multicenter Studies as Topic | 2 | 2012 | 1700 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2009 | 1810 | 0.040 |
Why?
|
Muscular Diseases | 1 | 2004 | 552 | 0.040 |
Why?
|
Aged | 14 | 2012 | 169092 | 0.040 |
Why?
|
Electrocardiography | 2 | 2011 | 6346 | 0.040 |
Why?
|
Male | 17 | 2012 | 360402 | 0.040 |
Why?
|
Oxidation-Reduction | 3 | 2012 | 2231 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2005 | 1386 | 0.040 |
Why?
|
Middle Aged | 13 | 2012 | 220603 | 0.040 |
Why?
|
Female | 16 | 2012 | 392203 | 0.040 |
Why?
|
Survival Rate | 1 | 2011 | 12719 | 0.030 |
Why?
|
Triglycerides | 1 | 2004 | 2459 | 0.030 |
Why?
|
Ultrasonography | 1 | 2009 | 5965 | 0.030 |
Why?
|
Inflammation | 4 | 2012 | 10759 | 0.030 |
Why?
|
Chronic Disease | 1 | 2011 | 9310 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2007 | 1937 | 0.030 |
Why?
|
Risk Factors | 5 | 2012 | 74128 | 0.030 |
Why?
|
Thiazoles | 1 | 2003 | 1517 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2004 | 1884 | 0.030 |
Why?
|
Time Factors | 2 | 2011 | 39908 | 0.030 |
Why?
|
Risk | 4 | 2012 | 9603 | 0.030 |
Why?
|
Prognosis | 3 | 2005 | 29601 | 0.030 |
Why?
|
Mortality | 1 | 2006 | 2899 | 0.030 |
Why?
|
Health Expenditures | 1 | 2007 | 2363 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2009 | 58919 | 0.030 |
Why?
|
Disease Progression | 1 | 2011 | 13495 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2012 | 80583 | 0.030 |
Why?
|
Lipids | 2 | 2002 | 3332 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2003 | 2234 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2005 | 12448 | 0.030 |
Why?
|
Swine | 1 | 2003 | 5908 | 0.030 |
Why?
|
Lipoprotein(a) | 2 | 2009 | 479 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2003 | 2118 | 0.020 |
Why?
|
Immunoglobulin M | 2 | 2009 | 1526 | 0.020 |
Why?
|
Organizational Case Studies | 1 | 2012 | 301 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5493 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2003 | 3085 | 0.020 |
Why?
|
Health Care Costs | 1 | 2003 | 3238 | 0.020 |
Why?
|
Risk Assessment | 2 | 2009 | 23974 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 2009 | 6403 | 0.020 |
Why?
|
Age Factors | 1 | 2007 | 18381 | 0.020 |
Why?
|
Logistic Models | 1 | 2004 | 13248 | 0.020 |
Why?
|
Organizational Innovation | 1 | 2012 | 537 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2005 | 15250 | 0.020 |
Why?
|
Autoantibodies | 2 | 2009 | 2115 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2003 | 12759 | 0.020 |
Why?
|
Blood Pressure | 1 | 2003 | 8473 | 0.020 |
Why?
|
Myocardial Revascularization | 1 | 2011 | 790 | 0.020 |
Why?
|
Lipoproteins | 1 | 2012 | 879 | 0.020 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2009 | 426 | 0.020 |
Why?
|
Interleukin-6 | 2 | 2007 | 3205 | 0.020 |
Why?
|
Physician's Role | 1 | 2012 | 917 | 0.020 |
Why?
|
Medical Informatics | 1 | 2012 | 732 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2003 | 11874 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2009 | 4533 | 0.020 |
Why?
|
Animals | 2 | 2009 | 168202 | 0.010 |
Why?
|
United States | 2 | 2007 | 72292 | 0.010 |
Why?
|
Apolipoprotein B-100 | 1 | 2004 | 157 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2003 | 18220 | 0.010 |
Why?
|
Thromboembolism | 1 | 2009 | 991 | 0.010 |
Why?
|
Solubility | 1 | 2004 | 1089 | 0.010 |
Why?
|
Patient Care Team | 1 | 2012 | 2515 | 0.010 |
Why?
|
Morbidity | 1 | 2006 | 1750 | 0.010 |
Why?
|
Cause of Death | 1 | 2011 | 3683 | 0.010 |
Why?
|
Simvastatin | 1 | 2002 | 346 | 0.010 |
Why?
|
Arteriosclerosis | 1 | 2004 | 1056 | 0.010 |
Why?
|
Troponin | 1 | 2003 | 502 | 0.010 |
Why?
|
ROC Curve | 1 | 2007 | 3575 | 0.010 |
Why?
|
Massachusetts | 1 | 2012 | 8835 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2012 | 3599 | 0.010 |
Why?
|
Pilot Projects | 1 | 2012 | 8619 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2012 | 4325 | 0.010 |
Why?
|
Atherosclerosis | 1 | 2012 | 3400 | 0.010 |
Why?
|
Heart Arrest | 1 | 2004 | 1513 | 0.010 |
Why?
|
Odds Ratio | 1 | 2004 | 9644 | 0.010 |
Why?
|
Adult | 1 | 2004 | 220995 | 0.010 |
Why?
|
Heart Failure | 1 | 2011 | 11670 | 0.000 |
Why?
|
Cohort Studies | 1 | 2009 | 41464 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15498 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 2002 | 10175 | 0.000 |
Why?
|